Multi asset growth and income opportunity – JPMorgan MATE portfolio

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) has announced the ten largest investments in % of total assets as a 30 November 2021.

JPMorgan Global High Yield Bond Fund10.1%
Infrastructure Investments Fund8.9%
MSCI EMGMKT (New Style) Index Equity (Future)3.8%
US 10YR (New Style) Bond Commodity (Future)3.8%
JPM Global Convertibles3.7%
JPMorgan Emerging Markets Debt Fund3.3%
EURO (New Style) Bond Commodity (Future)3.2%
JPM China A3.2%
Procter & Gamble2.9%
Coca-Cola2.4%
Total45.3%

JPMorgan Multi-Asset Growth & Income plc combines sustainable income and capital growth from globally diversified investments. The Trust aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Analog Devices sees growth accelerating

Analog Devices expects annual revenue growth to average 7% to 10% over the next five years, the chip maker told analysts at a meeting Tuesday morning at the company’s headquarters near Boston. As the name implies, Analog

US FDA approves new Bristol Myers cancer immunotherapy

Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The company

Procter & Gamble-owned Pantene partners with impressive female collective

THE WHAT? Procter & Gamble-owned Pantene has teamed up with ‘impressive, strong, modern, multi-hyphenate women’ to form the new Pantene Conditioner Collective. THE DETAILS Partners of the collective include Chloe Fineman, who features on Saturday Night Live and Dickinson, comedian Meg

Procter & Gamble’s sales jump

Shoppers shrugged off rising prices last year on products like Pampers diapers and Charmin toilet paper, Procter & Gamble said on Wednesday in announcing a jump in its second-quarter earnings. The consumer goods giant reported that

Abbvie looks to crack the cystic fibrosis code

When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about

Italy to receive 40,000 Merck antiviral drug doses next week

Italy will receive around 40,000 doses of Merck & Co’s (MRK.N) COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday. “They are intended